Connect with us

Health

Experimental women's cancer drug boosts survival rates in notable study

Published

on

Experimental women's cancer drug boosts survival rates in notable study

A new drug is showing promise in tackling treatment-resistant ovarian cancer.

Relacorilant, the drug tested in a phase 3 ROSELLA trial with Corcept Therapeutics in California, was found to improve overall survival and progression of the disease when matched with a chemotherapy drug called nab-paclitaxel.

The ROSELLA trial, conducted in collaboration with The GOG Foundation, analyzed 381 patients around the world, including the U.S., Europe, South Korea, Brazil, Argentina, Canada and Australia, according to a press release.

AI DETECTS OVARIAN CANCER BETTER THAN HUMAN EXPERTS IN NEW STUDY

The large, randomized phase 3 study revealed a 30% reduction in risk of disease progression in patients with platinum-resistant ovarian cancer, compared to those just treated with nab-paclitaxel. (Some types of chemotherapy contain the element platinum.)

Advertisement

Patients whose disease returns less than six months after receiving platinum-containing therapy have “platinum-resistant” disease, according to Corcept Therapeutics. (iStock)

The researchers also noted “significant improvement” in overall survival with this combination of drugs.

Relacorilant, which is administered as an oral pill, was reportedly “well-tolerated” by patients without increased side effects.

“A 30% decrease in risk of recurrence and a 31% decreased risk of death is promising.”

The drug is administered by mouth one day before, the day of and one day after nab-paclitaxel therapy, which is given via infusion every week.

Advertisement

The findings will be presented at a medical conference later this year, researchers say. Results from the Phase 2 were published in the Journal of Clinical Oncology in 2023.

OVARIAN CANCER TREATMENT ON FAST TRACK FOR FDA APPROVAL AS CHEMO ALTERNATIVES EMERGE: ‘WE’RE MAKING PROGRESS’

Ovarian cancer is the fifth most common cause of cancer death in women and is the deadliest of gynecologic cancers, according to the Ovarian Cancer Research Alliance.

Alexander B. Olawaiye, MD, director of gynecological cancer research at Magee-Women’s Hospital at the University of Pittsburgh and principal investigator in the ROSELLA trial, discussed the results with Fox News Digital.

Relacorilant, which is administered as an oral pill, was reportedly “well-tolerated” by patients without increased side effects. (iStock)

Advertisement

Olawaiye echoed that this new agent is the “first of its kind” in the battle against cancers that don’t have many treatment options.

“That’s what makes the findings of this study really exciting, because it did show a very significant improvement in both progression-free survival and overall survival,” he said.

OVARIAN CANCER SIGNS, SYMPTOMS, DIAGNOSIS AND TREATMENT OPTIONS

The expert shared his gratitude to his research team, mentioning that they “never stopped trying” for women undergoing treatment.

“I want to congratulate the women that are being treated for ovarian cancer — first, for helping us to do this trial and second, for the potential that we may now have another option on the block.”

Advertisement

Patients in the trial showed a 30% decrease in death risk, according to researchers. (iStock)

Dr. Brian Slomovitz, director of gynecologic oncology and co-chair of the Cancer Research Committee at Mount Sinai Medical Center in Miami Beach, Florida, also commented on these findings in an interview with Fox News Digital.

“We know ovarian cancer is very, very difficult to treat, particularly in those patients who have a disease that’s resistant to the standard chemotherapies,” he said.

“For a long time, we’ve been trying to find treatments that can help patients not only keep the disease away longer, but also live longer. And most of the trials, unfortunately, have been negative.”

CLICK HERE TO SIGN UP FOR OUR HEALTH NEWSLETTER

Advertisement

Slomovitz, a member of The GOG Foundation, said he considers the ROSELLA trial an “opportunity to use a unique drug” that has shown “positive, encouraging results.”

“A 30% decrease in risk of recurrence and a 31% decreased risk of death is promising,” he stated.

Relacorilant is administered one day before, the day of and one day after nab-paclitaxel chemotherapy, which is given via infusion every week. (iStock)

“To see data like this is refreshing, and it represents something that’s exciting for our patients who suffer from ovarian cancer.”

Olawaiye shared his hope for the treatment to receive clinical approval “pretty soon.”

Advertisement

For more Health articles, visit www.foxnews.com/health

As research and technology advance, various cancer treatments have surfaced in the last several years.

      

Olawaiye commented that the past two decades have been a “very exciting time,” as there’s been an “explosion of approvals” for cancer therapies.

“Today’s news about Relacorilant is just another addition,” he said.

Advertisement

Health

Heart disease threat projected to climb sharply for key demographic

Published

on

Heart disease threat projected to climb sharply for key demographic

NEWYou can now listen to Fox News articles!

A new report by the American Heart Association (AHA) included some troubling predictions for the future of women’s health.

The forecast, published in the journal Circulation on Wednesday, projected increases in various comorbidities in American females by 2050.

More than 59% of women were predicted to have high blood pressure, up from less than 49% currently.

The review also projected that more than 25% of women will have diabetes, compared to about 15% today, and more than 61% will have obesity, compared to 44% currently.

Advertisement

As a result of these risk factors, the prevalence of cardiovascular disease and stroke is expected to rise to 14.4% from 10.7%.

The prevalence of cardiovascular disease and stroke in women is expected to rise to 14.4% from 10.7% by 2050. (iStock)

Not all trends were negative, as unhealthy cholesterol prevalence is expected to drop to about 22% from more than 42% today, the report stated.

CLICK HERE TO DOWNLOAD THE FOX NEWS APP

Dr. Elizabeth Klodas, a cardiologist and founder of Step One Foods in Minnesota, commented on these “jarring findings.”

Advertisement

“The fact that on our current trajectory, cardiometabolic disease is projected to explode in women within one generation should be a huge wake-up call,” she told Fox News Digital.

NEARLY 90% OF AMERICANS AT RISK OF SILENT DISEASE — HERE’S WHAT TO KNOW

“Hypertension, diabetes, obesity — these are all major risk factors for heart disease, and we are already seeing what those risks are driving. Heart disease is the No. 1 killer of women, eclipsing all other causes of death, including breast cancer.”

Cardiovascular disease is the leading cause of death for women in the U.S. and around the world. (iStock)

Klodas warned that heart disease starts early, progresses “stealthily,” and can present “out of the blue in devastating ways.”

Advertisement

The AHA published another study on Thursday revealing one million hospitalizations, showing that heart attack deaths are climbing among adults below the age of 55.

The more alarming finding, according to Klodas, is that young women were found more likely to die after their first heart attack than men of the same age.

DOCTOR SHARES 3 SIMPLE CHANGES TO STAY HEALTHY AND INDEPENDENT AS YOU AGE

“This is all especially tragic since heart disease is almost entirely preventable,” she said. “The earlier you start, the better.”

Children can show early evidence of plaque deposition in their arteries, which can be reversed through lifestyle changes if “undertaken early enough and aggressively enough,” according to the expert.

Advertisement

Moving more is one part of protecting a healthy heart, according to experts. (iStock)

Klodas suggested that rising heart conditions are associated with traditional risk factors, like smoking, high blood pressure, high cholesterol, diabetes, obesity and a sedentary lifestyle.

CLICK HERE FOR MORE HEALTH STORIES

Doctors are also seeing higher rates of preeclampsia, or high blood pressure during pregnancy, as well as gestational diabetes. Klodas noted that these are sex-specific risk factors that don’t typically contribute to complications until after menopause.

The best way to protect a healthy heart is to “do the basics,” Klodas recommended, including the following lifestyle habits.

Advertisement

CLICK HERE TO SIGN UP FOR OUR HEALTH NEWSLETTER

Klodas especially emphasized making improvements to diet, as the food people eat affects “every single risk factor that the AHA’s report highlights.”

“High blood pressure, high blood sugar, high cholesterol, excess weight – these are all conditions that are driven in part or in whole by food,” she said. “We eat multiple times every single day, which means what we eat has profound cumulative effects over time.”

“Even a small improvement in dietary intake, when maintained, can have a massive positive impact on health,” a doctor said. (iStock)

“Even a small improvement in dietary intake, when maintained, can have a massive positive impact on health.”

Advertisement

The doctor also recommends changing out a few snacks per day for healthier choices, which has been proven to “yield medication-level cholesterol reductions” in a month.

TEST YOURSELF WITH OUR LATEST LIFESTYLE QUIZ

“Keep up that small change and, over the course of a year, you could also lose 20 pounds and reduce your sodium intake enough to avoid blood pressure-lowering medications,” Klodas added.

“Women should not view the AHA report as inevitable. We have power over our health destinies. We just need to use it.”

Advertisement

Related Article

3 simple lifestyle changes could add almost a decade to your life, research shows
Continue Reading

Health

Vanessa Williams, 62, Opens up About Weight Loss and HRT After Menopause

Published

on

Vanessa Williams, 62, Opens up About Weight Loss and HRT After Menopause


Advertisement




Vanessa Williams Opens up About Weight Loss and HRT | Woman’s World




















Advertisement





Advertisement


Use left and right arrow keys to navigate between menu items.


Use escape to exit the menu.

Advertisement

Continue Reading

Health

Common vision issue linked to type of lighting used in Americans’ homes

Published

on

Common vision issue linked to type of lighting used in Americans’ homes

NEWYou can now listen to Fox News articles!

Nearsightedness (myopia) is skyrocketing globally, with nearly half of the world’s population expected to be myopic by 2050, according to the World Health Organization.

Heavy use of smartphones and other devices is associated with an 80% higher risk of myopia when combined with excessive computer use, but a new study suggests that dim indoor lighting could also be a factor.

For years, scientists have been puzzled by the different ways myopia is triggered. In lab settings, it can be induced by blurring vision or using different lenses. Conversely, it can be slowed by something as simple as spending time outdoors, research suggests.

Nearsightedness occurs when the eyeball grows too long from front to back, according to the American Optometric Association (AOA). This physical elongation causes light to focus in front of the retina rather than directly on it, making distant objects appear blurry.

Advertisement

The study suggests that myopia isn’t caused by the digital devices themselves, but by the low-light environments where they are typically used. (iStock)

Researchers at the State University of New York (SUNY) College of Optometry identified a potential specific trigger for this growth. When someone looks at a phone or a book up close, the pupil naturally constricts.

COMMON VISION ISSUE COULD LEAD TO MISSED CANCER WARNING, STUDY FINDS

“In bright outdoor light, the pupil constricts to protect the eye while still allowing ample light to reach the retina,” Urusha Maharjan, a SUNY Optometry doctoral student who conducted the study, said in a press release.

CLICK HERE TO DOWNLOAD THE FOX NEWS APP

Advertisement

“When people focus on close objects indoors, such as phones, tablets or books, the pupil can also constrict — not because of brightness, but to sharpen the image,” she went on. “In dim lighting, this combination may significantly reduce retinal illumination.”

High-intensity natural light prevents myopia because it provides enough retinal stimulation to override the “stop growing” signal, even when pupils are constricted. (iStock)

The hypothesis suggests that when the retina is deprived of light during extended close-up work, it sends a signal for the eye to grow.

In a dim environment, the narrowed pupil allows so little light through that the retinal activity isn’t strong enough to signal the eye to stop growing, the researchers found.

CLICK HERE TO SIGN UP FOR OUR HEALTH NEWSLETTER

Advertisement

In contrast, being outdoors provides light levels much brighter than indoors. This ensures that even when the pupil narrows to focus on a nearby object, the retina still receives a strong signal, maintaining healthy eye development.

CLICK HERE FOR MORE HEALTH STORIES

The team noted some limitations of the study, including the small subject group and the inability to directly measure internal lens changes, as the bright backgrounds used to mimic the outdoors made pupils too small for standard equipment.

Researchers believe that increasing indoor brightness during close-up work could be a simple, testable way to slow the global nearsightedness epidemic. (iStock)

“This is not a final answer,” Jose-Manuel Alonso, MD, PhD, SUNY distinguished professor and senior author of the study, said in the release.

Advertisement

TEST YOURSELF WITH OUR LATEST LIFESTYLE QUIZ

“But the study offers a testable hypothesis that reframes how visual habits, lighting and eye focusing interact.”

The study was published in the journal Cell Reports.

Related Article

Common diabetes drug may help preserve eyesight as people age
Continue Reading

Trending